Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00725309 · ClinicalTrials.gov registry record
Evaluating Genetic Factors That May Contribute to Elastin Function and the Development of Chronic Obstructive Pulmonary Disease
A clinical trial of Pulmonary Disease, Chronic Obstructive and Emphysema, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- 255
- Enrollment target
- 1
- Study location
NCT00725309 is a study of Pulmonary Disease, Chronic Obstructive and Emphysema that has completed, run by Washington University School of Medicine. The registered enrollment target is 255 participants, below the 1,041-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00725309, a study of Pulmonary Disease, Chronic Obstructive and Emphysema, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- 255 participants
- Enrollment target
- 1
- Study location
Study Summary
Chronic obstructive pulmonary disease (COPD) is a lung disease that is primarily caused by cigarette smoking. The breakdown of elastin, a protein found in the lungs, can cause lung damage and may contribute to the development of COPD. Some people may be more prone to elastin damage and in turn to developing COPD than others. This study will examine whether genetic factors are responsible for altering elastin function and increasing the risk of developing COPD.
Conditions Studied
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2007-11 |
| Est. Completion | 2017-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00725309
The ClinicalTrials.gov registry entry for NCT00725309 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,041-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (76% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 0 interventions.
NCT00725309 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT00725309 about?
NCT00725309 is a clinical study titled "Evaluating Genetic Factors That May Contribute to Elastin Function and the Development of Chronic Obstructive Pulmonary Disease". Chronic obstructive pulmonary disease (COPD) is a lung disease that is primarily caused by cigarette smoking. The breakdown of elastin, a protein found in the lungs, can cause lung damage and may contribute to the development of COPD. Some people may be more prone to elastin damage and in turn to de...
What is the current status of trial NCT00725309?
This trial is currently completed. The enrollment target is 255 participants. The study started on 2007-11. Estimated completion is 2017-12.
What conditions does trial NCT00725309 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive, Emphysema.
Who is sponsoring clinical trial NCT00725309?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00725309 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
RECRUITING · Phase 3
-
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 1
-
Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD
RECRUITING · NA
-
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
RECRUITING · Phase 3
-
Trial to Determine Effective Aspirin Dose in COPD
RECRUITING · Phase 3
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.